Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects.
Glimepiride and atorvastatin in combination are commonly employed for treating the hyperglycemia and dyslipidemia, respectively, in patients of type 2 diabetes. The present study was designed to find out the influence of atorvastatin on urinary excretion and renal clearance of Glimepiride in healthy adult male volunteers. In each experimental subject, Glimepiride 2mg was given orally after an overnight fasting. Samples of blood and urine were taken at different specific time intervals. After a washout period of ten days, Glimepiride 2mg was co-administered with atorvastatin 20mg orally. Post-medication, blood and urine samples were collected following the same sampling schedule as for Glimepiride alone. The samples were analyzed for Glimepiride and creatinine concentration by HPLC-UV and Spectrophotometer, respectively. Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively. Atorvastatin decreased the urinary excretion and renal clearance of Glimepiride due to which chances of hypoglycemia provokes and renal handling of Glimepiride involves back diffusion besides glomerular filtration and no influence of atorvastatin was seen on these mechanisms.
Institute of Pharmacy, Physiology and Pharmacology, University of Agriculture, Faisalabad, Pakistan.
Tayyaba
T
Sana
Institute of Pharmacy, Physiology and Pharmacology, University of Agriculture, Faisalabad, Pakistan.
Bilal
B
Aslam
Department of Applied Chemistry and Biochemistry, Government College University, Faisalabad, Pakistan.
Nosheen
N
Aslam
Department of Eastern Medicine, Directorate of Medical Sciences, Government College University, Faisalabad, Pakistan.
Muhammad Mudassar
MM
Ashraf
Department of Zoology, Government College University, Faisalabad, Pakistan.
Asma
A
Ashraf
Department of Pharmacy, The University of Lahore, Islamabad Campus, Pakistan.
Tahir Aqeel
TA
Malik
College of Allied Health Professionals, Directorate of Medical Sciences, Government College University, Faisalabad, Pakistan.
Sammia Gul
SG
Niazi
College of Allied Health Professionals, Directorate of Medical Sciences, Government College University, Faisalabad, Pakistan.
Imtiaz Mahmood
IM
Tahir
College of Allied Health Professionals, Directorate of Medical Sciences, Government College University, Faisalabad, Pakistan.
Muhammad
M
RiazurRehman
Department of Eastern Medicine, Directorate of Medical Sciences, Government College University, Faisalabad, Pakistan.
Hamad
H
Ahmed
D000328:Adult; D000069059:Atorvastatin / Q000008:administration & dosage* / Q000009:adverse effects; D002851:Chromatography, High Pressure Liquid; D065729:Cytochrome P-450 CYP2C9 / Q000378:metabolism; D065688:Cytochrome P-450 CYP2C9 Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D004347:Drug Interactions; D064368:Healthy Volunteers; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000652:urine*; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D065667:Renal Elimination / Q000187:drug effects*; D013056:Spectrophotometry, Ultraviolet; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000652:urine*
D065688:Cytochrome P-450 CYP2C9 Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; C057619:glimepiride; D000069059:Atorvastatin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9